Current Diabetes Reports

, Volume 9, Issue 3, pp 193–199 | Cite as

Pathophysiology of prediabetes

  • Muhammad A. Abdul-GhaniEmail author
  • Ralph A. DeFronzo


The term prediabetes refers to subjects with impaired fasting glucose and/or impaired glucose tolerance who are at increased risk for type 2 diabetes mellitus. Although both types of patients are at increased risk for developing type 2 diabetes mellitus and cardiovascular disease, they manifest distinct metabolic abnormalities. In this article, we summarize the metabolic abnormalities that characterize each state and the contribution of these metabolic abnormalities to the increased risk of diabetes and cardiovascular disease.


Insulin Resistance Impaired Glucose Tolerance Impaired Fasting Glucose Normal Glucose Tolerance Plasma Glucose Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Classification and diagnosis of diabetes and other categories of glucose intolerance [no authors listed]. Diabetes 1979, 28:1039–1057.Google Scholar
  2. 2.
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus [no authors listed]. Diabetes Care 1997, 20:1183–1197.Google Scholar
  3. 3.
    Genuth S, Alberti KG, Bennett P, et al.: Expert Committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26:3160–3167.PubMedCrossRefGoogle Scholar
  4. 4.
    Unwin N, Shaw J, Zimmet P, Alberti KG: Impaired glucose tolerance and impaired fasting glycemia: the current status on definition and intervention. Diabet Med 2002, 19:708–723.PubMedCrossRefGoogle Scholar
  5. 5.
    Choi KM, Lee J, Kim DR, et al.: Comparison of ADA and WHO criteria for the diagnosis of diabetes in elderly Koreans. Diabet Med 2002, 19:853–857.PubMedCrossRefGoogle Scholar
  6. 6.
    Gabir MM, Hanson RL, Dabelea D, et al.: The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000, 23:1108–1112.PubMedCrossRefGoogle Scholar
  7. 7.
    Dunstan DW, Zimmet PZ, Welborn TA, et al.: The rising prevalence of diabetes mellitus and impaired glucose tolerance: the Australian diabetes, obesity and lifestyle study. Diabetes Care 2002, 25:829–834.PubMedCrossRefGoogle Scholar
  8. 8.
    Shaw JE, Zimmet PZ, de Courten M, et al.: Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in mauritius? Diabetes Care 1999, 22:399–402.PubMedCrossRefGoogle Scholar
  9. 9.
    Larsson H, Berglund G, Lindgarde F, Ahren B: Comparison of ADA and WHO criteria for diagnosis of diabetes and glucose intolerance. Diabetologia 1998, 41:1124–1125.PubMedCrossRefGoogle Scholar
  10. 10.
    de Vegt F, Dekker JM, Stehouwer CD, et al.: The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn Study. Diabetes Care 1998, 21:1686–1690.PubMedCrossRefGoogle Scholar
  11. 11.
    Harris MI, Eastman RC, Cowie CC, et al.: Comparison of diabetes diagnostic categories in the U.S. population according to the 1997 American Diabetes Association and 198085 World Health Organization diagnostic criteria. Diabetes Care 1997, 20:1859–1862.PubMedCrossRefGoogle Scholar
  12. 12.
    Ko GT, Chan JC, Woo J, Cockram CS: Use of the 1997 American Diabetes Association diagnostic criteria for diabetes in a Hong Kong Chinese population. Diabetes Care 1998, 21:2094–2097.PubMedCrossRefGoogle Scholar
  13. 13.
    Abdul-Ghani MA, Tripathy D, DeFronzo RA: Contribution of beta cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006, 29:1130–1139.PubMedCrossRefGoogle Scholar
  14. 14.
    Abdul-Ghani MA, Jenkinson C, Richardson D, DeFronzo RA: Insulin secretion and insulin action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study (VAGES) Diabetes 2006, 55:1430–1435.PubMedCrossRefGoogle Scholar
  15. 15.
    Weyer C, Bogardus C, Pratley RE: Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 1999, 48:2197–2203.PubMedCrossRefGoogle Scholar
  16. 16.
    Wasada T, Kuroki H, Katsumori K, et al.: Who are more insulin resistant, people with IFG or people with IGT? Diabetologia 2004, 47:758–759.PubMedCrossRefGoogle Scholar
  17. 17.
    Festa A, D’Agostino R Jr, Hanley AJ, et al.: Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes 2004, 53:1549–1555.PubMedCrossRefGoogle Scholar
  18. 18.
    Osei K, Gaillard T, Schuster DP: Pathogenetic mechanisms of impaired glucose tolerance and type II diabetes in African-Americans. The significance of insulin secretion, insulin sensitivity, and glucose effectiveness. Diabetes Care 1997, 20:396–404.PubMedCrossRefGoogle Scholar
  19. 19.
    van Haeften TW, Pimenta W, Mitrakou A, et al.: Disturbances in beta-cell function in impaired fasting glycemia. Diabetes 2002, 51(Suppl 1):S265–S270.PubMedCrossRefGoogle Scholar
  20. 20.
    Pimenta WP, Santos ML, Cruz NS, et al.: Brazilian individuals with impaired glucose tolerance are characterized by impaired insulin secretion. Diabetes Metab 2002, 28:468–476.PubMedGoogle Scholar
  21. 21.
    Abdul-Ghani MA, Sabbah M, Kher J, et al.: Different contributions of insulin resistance and beta-cell dysfunction in overweight Israeli Arabs with IFG and IGT. Diabetes Metab Res Rev 2006, 22:126–130.PubMedCrossRefGoogle Scholar
  22. 22.
    Davidson MB, Landsman PB, Alexander CM: Lowering the criterion for impaired fasting glucose will not provide clinical benefit. Diabetes Care 2003, 26:3329–3330.PubMedCrossRefGoogle Scholar
  23. 23.
    Will new diagnostic criteria for mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group [no authors listed]. BMJ 1998, 317:371–375.Google Scholar
  24. 24.
    Qiao Q, Hu G, Tuomilehto J, et al.: Age and sex specific prevalence of diabetes and impaired glucose regulation in 13 European cohorts [abstract 37]. Presented at the 37th Annual Meeting of the European Diabetes Epidemiology Group. Oxford, UK; March 23–26, 2002.Google Scholar
  25. 25.
    Qiao Q, Nakagami T, Tuomilehto J, et al.: Comparison of the fasting and the 2-hour glucose criteria for diabetes in different Asian cohorts. Diabetologia 2000, 43:1470–1475.PubMedCrossRefGoogle Scholar
  26. 26.
    Qiao Q, Hu G, Tuomilehto J, et al.: Age and sex specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care 2003, 26:1770–1780.PubMedCrossRefGoogle Scholar
  27. 27.
    Groop LC, Bonadonna RC, DelPrato S, et al.: Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 1989, 84:205–213.PubMedCrossRefGoogle Scholar
  28. 28.
    Jani R, Molina M, Matsuda M, et al.: Decreased noninsulin dependent glucose clearance contributes to the rise in FPG in the non-diabetic range. Diabetes Care 2008, 31:311–315.PubMedCrossRefGoogle Scholar
  29. 29.
    Abdul-Ghani MA, Tripathy D, Jenkinson C, et al.: Adipocytes in subjects with impaired fasting glucose and impaired glucose tolerance are resistant to the antilipolytic effect of insulin. Acta Diabetol 2008, 45:147–150.PubMedCrossRefGoogle Scholar
  30. 30.
    Reaven GM, Hollenbeck C, Jeng CY, et al.: Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988, 37:1020–1024.PubMedCrossRefGoogle Scholar
  31. 31.
    DeFronzo RA: Dysfunctional fat cells, lipotoxicity and type 2 diabetes. Int J Clin Pract 2004, 143(Suppl):9–21.CrossRefGoogle Scholar
  32. 32.
    DeFronzo RA: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 1997, 50:191–197.PubMedCrossRefGoogle Scholar
  33. 33.
    Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595–1607.PubMedCrossRefGoogle Scholar
  34. 34.
    Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52:1210–1214.PubMedCrossRefGoogle Scholar
  35. 35.
    Cersosimo E, DeFronzo RA: Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006, 22:423–436.PubMedCrossRefGoogle Scholar
  36. 36.
    Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003, 46:3–19.PubMedCrossRefGoogle Scholar
  37. 37.
    Abdul-Ghani MA, Jenkinson C, Richardson D, DeFronzo RD: Impaired early but not late phase insulin secretion in subjects with impaired fasting glucose. Eur J Clin Invest 2009 (in press).Google Scholar
  38. 38.
    Meyer C, Pimenta W, Woerle HJ, et al.: Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 2006, 29:1909–1914.PubMedCrossRefGoogle Scholar
  39. 39.
    Ferrannini E, Gastaldelli A, Miyazaki Y, et al.: Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005, 90:493–500.PubMedCrossRefGoogle Scholar
  40. 40.
    Laakso M, Zilinskaite J, Hansen T, et al.: Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia 2008, 51:502–511.PubMedCrossRefGoogle Scholar
  41. 41.
    Abdul-Ghani MA, Matsuda M, Jenkinson C, et al.: The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance. Am J Physiol 2008, 295:E401–E406.Google Scholar
  42. 42.
    Gastaldelli A, Ferrannini E, Miyazaki Y, et al.: Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004, 47:31–39.PubMedCrossRefGoogle Scholar
  43. 43.
    DeFronzo RA: From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes. Diabetes 2009 (in press).Google Scholar
  44. 44.
    Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22:233–240.PubMedCrossRefGoogle Scholar
  45. 45.
    Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria [no authors listed]. Arch Intern Med 2001, 161:397–405.Google Scholar
  46. 46.
    Saydah SH, Miret M, Sung J, et al.: Post-challenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care 2001, 24:1397–1402.PubMedCrossRefGoogle Scholar
  47. 47.
    Barzilay JI, Spiekerman CF, Wahl PW, et al.: Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 1999, 354:622–625.PubMedCrossRefGoogle Scholar
  48. 48.
    DeFronzo RA: Is insulin resistance atherogenic? Possible mechanisms. Atheroscler Suppl 2006, 7:11–15.PubMedCrossRefGoogle Scholar
  49. 49.
    Gungor N, Hannon T, Libman I, et al.: Type 2 diabetes mellitus in youth: the complete picture to date. Pediatr Clin North Am 2005, 52:1579–1609.PubMedCrossRefGoogle Scholar
  50. 50.
    Cali AM, Caprio S: Prediabetes and type 2 diabetes in youth: an emerging epidemic disease? Curr Opin Endocrinol Diabetes Obes 2008, 15:123–127.PubMedGoogle Scholar
  51. 51.
    Cali AM, Bonadonna RC, Trombetta M, et al.: Metabolic abnormalities underlying the different prediabetic phenotypes in obese adolescents. J Clin Endocrinol Metab 2008, 93:1767–1773.PubMedCrossRefGoogle Scholar
  52. 52.
    Cali AM, Man CD, Cobelli C, et al.: Primary defects in beta-cell function further exacerbated by worsening of insulin resistance mark the development of impaired glucose tolerance in obese adolescents. Diabetes Care 2009, 32:456–461.PubMedCrossRefGoogle Scholar
  53. 53.
    Cook S, Weitzman M, Auinger P, et al.: Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med 2003, 157:821–827.PubMedCrossRefGoogle Scholar
  54. 54.
    Williams DE, Cadwell BL, Cheng YJ, et al.: Prevalence of impaired fasting glucose and its relationship with cardiovascular disease risk factors in US adolescents, 1999–2000. Pediatrics 2005, 116:1122–1126.PubMedCrossRefGoogle Scholar
  55. 55.
    Weiss R, Taksali SE, Tamborlane WV, et al.: Predictors of changes in glucose tolerance status in obese youth. Diabetes Care 2005, 28:902–909.PubMedCrossRefGoogle Scholar
  56. 56.
    Abdul-Ghani MA, Matsuda M, DeFronzo RA: Strong association between insulin resistance in liver and skeletal muscle in non-diabetic subjects. Diabet Med 2008, 25:1289–1294.PubMedGoogle Scholar
  57. 57.
    Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin [no authors listed]. N Engl J Med 2002, 346:393–403.Google Scholar
  58. 58.
    Tuomilehto J, Lindstrom J, Eriksson JG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343–1350.PubMedCrossRefGoogle Scholar
  59. 59.
    Haffner S, Temprosa M, Crandall J, et al.: Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005, 54:1566–1572.PubMedCrossRefGoogle Scholar
  60. 60.
    Knowler WC, Hamman RF, Edelstein SL, et al.: Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005, 54:1150–1156.PubMedCrossRefGoogle Scholar
  61. 61.
    Gerstein HC, Yusuf S, Bosch J, et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096–1105.PubMedCrossRefGoogle Scholar
  62. 62.
    Nathan DM, Davidson MB, DeFronzo RA, et al.: Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007, 30:753–759.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Diabetes DivisionUniversity of Texas Health Science Center at San AntonioSan AntonioUSA

Personalised recommendations